Capital Fund Management S.A. Cuts Stock Position in Haleon plc (NYSE:HLN)

Capital Fund Management S.A. reduced its stake in Haleon plc (NYSE:HLN - Free Report) by 75.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 54,421 shares of the company's stock after selling 168,779 shares during the period. Capital Fund Management S.A.'s holdings in Haleon were worth $519,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Sierra Ocean LLC bought a new stake in Haleon during the 4th quarter valued at about $26,000. Versant Capital Management Inc increased its position in shares of Haleon by 2,029.1% during the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company's stock valued at $34,000 after acquiring an additional 3,348 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Haleon during the fourth quarter valued at approximately $35,000. Spire Wealth Management purchased a new position in Haleon in the 4th quarter worth approximately $39,000. Finally, FIL Ltd boosted its stake in Haleon by 45.7% during the 4th quarter. FIL Ltd now owns 4,049 shares of the company's stock valued at $39,000 after purchasing an additional 1,270 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Sanford C. Bernstein downgraded Haleon from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Haleon in a research note on Monday, March 3rd. Morgan Stanley downgraded shares of Haleon from an "overweight" rating to an "equal weight" rating in a research report on Friday, January 10th. Hsbc Global Res cut Haleon from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. Finally, HSBC reaffirmed a "hold" rating on shares of Haleon in a report on Wednesday, March 5th. Six equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $10.95.

Haleon Stock Performance

Shares of HLN stock traded up $0.27 during mid-day trading on Tuesday, reaching $10.46. 3,896,866 shares of the company's stock traded hands, compared to its average volume of 11,254,357. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The firm has a market capitalization of $47.21 billion, a PE ratio of 30.78, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24. Haleon plc has a 12 month low of $8.12 and a 12 month high of $10.80. The firm has a 50 day moving average price of $10.10 and a two-hundred day moving average price of $9.80.

Haleon (NYSE:HLN - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.38 billion. On average, research analysts forecast that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The company also recently announced a -- dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be paid a dividend of $0.1166 per share. This is a boost from Haleon's previous -- dividend of $0.05. The ex-dividend date of this dividend is Friday, April 25th. This represents a yield of 1.6%. Haleon's dividend payout ratio (DPR) is presently 58.97%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.